Excerpt
120 low-income countries to get cheap HIV prevention drug
Manufacturing Company, Gilead Sciences, has announced that cheaper versions of the “gamechanger” HIV prevention drug, lenacapavir, will be made available in 120 low and middle-income countries.
Currently, the drug is priced at $42,250 annually in the US under the brand name Sunlenca, but researchers believe it could be produced for as low as $40 (£30) for a patient per year.
According to The Guardian, UK, the company had signed agreements with six manufacturers to produce and sell generic versions of lenacapavir in 120 “high-incidence, resource-limited” countries, primarily lower-income nations.
In the interim, the company would provide its products, focusing on registration in 18 countries with high HIV rates, including Botswana and South Africa.
It stated that Lenacapavir, which requires only two injections per year, has demonstrated impressive efficacy in preventing HIV.
Gilead disclosed that the drug stopped infections in clinical trials on girls and women in South Africa and Uganda, while a separate trial among men in countries like Argentina, Brazil, and South Africa showed nearly complete protection.
All the views expressed in, and at the source of, this article may not necessarily reflect those of T.E.A. Watchers.
Click article heading to go to article source.